ESC TV Today – Your Cardiovascular News
Season 3 - Ep.8: Extended interview on dual antiplatelet therapy in 2025
Jan 30, 2025
Gilles Montalescot, a Professor of Cardiology at Pitié University Hospital, dives into the evolving landscape of antiplatelet therapy for coronary syndromes. He discusses the importance of adapting treatment recommendations based on new research and patient diversity. The conversation highlights the complexities of managing dual therapy in high-risk patients and the critical balance between reducing ischemic risks and preventing bleeding. Montalescot also emphasizes the need for innovative strategies for timely interventions in STEMI patients.
14:42
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Recent shifts in dual antiplatelet therapy guidelines emphasize reducing therapy duration for chronic coronary syndrome to improve patient outcomes.
- Management of high-risk patients requires individualized antiplatelet strategies, highlighting the importance of a multidisciplinary approach for optimal care.
Deep dives
Evolving Guidelines for Antiplatelet Therapy
Changes in antiplatelet therapy guidelines for both acute and chronic coronary syndromes are influenced significantly by new research and evolving patient profiles. Over the past two decades, numerous studies have emerged that challenge long-standing recommendations, particularly regarding the duration of dual antiplatelet therapy. For chronic coronary syndrome, it is now recommended that patients primarily remain on a single agent, typically aspirin, while dual therapy, involving aspirin and a P2Y12 inhibitor like clopidogrel, is limited to one to three months post-stenting. This reflects a shift from reliance on older antiplatelet options towards more targeted and short-term treatment protocols based on contemporary evidence.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
